RetiVue

Executive Summary

RetiVue, founded in 2019 and headquartered in San Diego, is a privately held medical device company specializing in innovative ophthalmic diagnostic solutions. The company has developed ultrawidefield retinal imaging systems that deliver high-quality, affordable retinal photography suitable for patients ranging from infants to adults. RetiVue’s core mission is to prevent blindness in underserved and medically at-risk populations by enabling early documentation of eye disease. By addressing the gap in accessible retinal screening, the company aims to improve outcomes for conditions such as diabetic retinopathy, retinopathy of prematurity, and glaucoma in community health settings. RetiVue’s technology differentiates itself through a combination of portability, cost-effectiveness, and image quality, positioning it as a scalable alternative to traditional fundus cameras. The global market for retinal imaging is expanding due to rising diabetes prevalence and aging populations, particularly in low-resource environments. With strategic partnerships and potential FDA clearances for expanded indications, RetiVue is poised for growth. The company’s focus on underserved demographics and its product’s adaptability across age groups provide a strong value proposition, though commercial traction and funding details remain undisclosed.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for next-generation ultrawidefield imaging system75% success
• Q4 2026Partnership with major healthcare system for pilot deployment in underserved communities60% success
• 2026Publication of clinical validation study demonstrating improved detection rates in diabetic retinopathy screening80% success